EATONTOWN, N.J., Aug. 31 /PRNewswire-FirstCall/ -- Osteotech, Inc.
(Nasdaq: OSTE) announces the release of the Graftech(R) Lordotic Cervical
Spacer, the newest addition to Osteotech's Graftech(R) Bio-Implant product
line. The Graftech(R) Lordotic Cervical Spacer features 7 degrees of
lordosis, and, along with the Graftech(R) Cervical Spacer, is engineered from
dense cancellous tissue. Osteotech's two cervical spacer alternatives will
provide surgeons with a number of choices to conform to a patient's spinal
anatomy. The Graftech(R) Lordotic Cervical Spacer is available in a range of
heights and sizes and utilizes existing instrumentation already available to
surgeons.
Sam Owusu-Akyaw, Osteotech's President and Chief Operating Officer,
stated, "The life blood of any orthobiologic company is its ability to
introduce new products and technologies that meet the needs of surgeons and
patients. Osteotech was the first company to bring to market the technology
of utilizing dense cancellous tissue in a weight-bearing cervical spacer
application. We're particularly pleased that we can expand upon this
innovation with the introduction of a lordotic spacer to complement our line
of non-lordotic dense cancellous cervical spacers."
Mr. Owusu-Akyaw continued, "We anticipate introducing several new products
in 2005. In April 2005 we announced the introduction of Grafton(R) DBM
Orthoblend and now, the Graftech(R) Lordotic Cervical Spacer. We expect to be
announcing the release of a completely new line of products later this year."
Certain statements made throughout this press release that are not
historical facts contain forward-looking statements (as such are defined in
the Private Securities Litigation Reform Act of 1995) regarding the Company's
future plans, objectives and expected performance. Any such forward-looking
statements are based on assumptions that the Company believes are reasonable,
but are subject to a wide range of risks and uncertainties and, therefore,
there can be no assurance that actual results may not differ materially from
those expressed or implied by such forward-looking statements. Factors that
could cause actual results to differ materially include, but are not limited
to, differences in anticipated and actual product and service introduction
dates, the ultimate success of those products in the market place, the
continued acceptance and growth of current products and services, the impact
of competitive products and services, the availability of sufficient
quantities of suitable donated tissue and the success of cost control and
margin improvement efforts. Certain of these factors are detailed from time to
time in the Company's periodic reports (including the Annual Report on Form
10-K for the year ended December 31, 2004 and the Form 10-Q for the each of
the first two quarters of 2005) filed with the Securities and Exchange
Commission. All information in this press release is as of August 31, 2005
and the Company undertakes no duty to update this information.
Osteotech, Inc., headquartered in Eatontown, New Jersey, is a leading
provider of human bone and bone connective tissue for transplantation and an
innovator in the development and marketing of biomaterial and implant products
for musculoskeletal surgery. For further information regarding Osteotech or
this press release, please go to Osteotech's website homepage at
http://www.osteotech.com and to Osteotech's Financial Information Request Form
website page at http://www.osteotech.com/finrequest.htm.
SOURCE Osteotech, Inc.
 back to top
Related links:
http://www.osteotech.com
http://www.osteotech.com/finrequest.htm
Company News On-Call:
http://www.prnewswire.com/comp/668050.html
CONTACT:
Michael J. Jeffries, Osteotech, Inc.,
+1-732-542-2800; or Ivette Almeida, The Global Consulting Group,
+1-212-983-1702, ext. 209
|
